Study Evaluating Intepirdine (RVT-101) in Subjects With Mild to Moderate Alzheimer's Disease on Donepezil: MINDSET Study
A Phase 3, Double-blind, Randomized Study of RVT-101 Versus Placebo When Added to Existing Stable Donepezil Treatment in Subjects With Mild to Moderate Alzheimer's Disease
Sponsor: Axovant Sciences Ltd.
This PHASE3 trial investigates Alzheimer's Disease and is currently completed. Axovant Sciences Ltd. leads this study, which shows 14 recorded versions since 2015 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Dec 2020 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 9 earlier versions
-
Jan 2019 — Dec 2020 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2019 [monthly]
Completed PHASE3
-
Feb 2018 — Jun 2018 [monthly]
Completed PHASE3
-
Oct 2017 — Feb 2018 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Aug 2017 — Oct 2017 [monthly]
Active Not Recruiting PHASE3
-
Jul 2017 — Aug 2017 [monthly]
Active Not Recruiting PHASE3
-
Mar 2017 — Jul 2017 [monthly]
Active Not Recruiting PHASE3
-
Feb 2017 — Mar 2017 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE3
First recorded
Oct 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Axovant Sciences Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .